Inhibikase Therapeutics, an early stage biotech developing kinase inhibitors for Parkinson's and related disorders, raised $18 million by offering 1.8 million shares at $10, the low end of the range of $10 to $12. The company originally filed in July 2020 but postponed in November. It most recently planned to offer 1.4 million shares. At pricing, Inhibikase commands a fully diluted market value of $132 million.
Inhibikase Therapeutics plans to list on the Nasdaq under the symbol IKT. ThinkEquity acted as a lead manager on the deal.
